Last reviewed · How we verify
Temozolomide Plus Cisplatin
Temozolomide is an alkylating agent that works by interfering with DNA replication, while cisplatin is a platinum-based chemotherapy drug that works by cross-linking DNA, thereby inhibiting cancer cell growth.
Temozolomide is an alkylating agent that works by interfering with DNA replication, while cisplatin is a platinum-based chemotherapy drug that works by cross-linking DNA, thereby inhibiting cancer cell growth. Used for Glioblastoma, Malignant glioma.
At a glance
| Generic name | Temozolomide Plus Cisplatin |
|---|---|
| Also known as | Temodal., cisplatinum |
| Sponsor | Peking University Cancer Hospital & Institute |
| Drug class | alkylating agent, platinum-based chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Temozolomide and cisplatin are both used in chemotherapy to treat various types of cancer. They work by targeting rapidly dividing cancer cells and inhibiting their growth. Temozolomide is particularly effective against glioblastoma, while cisplatin is used to treat a range of cancers, including lung, bladder, and testicular cancer.
Approved indications
- Glioblastoma
- Malignant glioma
Common side effects
- Nausea
- Vomiting
- Fatigue
- Hair loss
- Anemia
Key clinical trials
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas (PHASE1)
- Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer (PHASE2)
- A Phase II Trial of LM103 in Advanced Melanoma (PHASE2)
- Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation (EARLY_PHASE1)
- Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery (PHASE2)
- A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN). (PHASE2, PHASE3)
- Embryonal Tumor With Multilayered Rosettes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: